Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.

Autor: Zhong J; State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Fei K; State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Wu L; Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China., Li B; Beijing Chest Hospital, Capital Medical University, Beijing, China., Wang Z; State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Cheng Y; Jilin Cancer Hospital, Changchun, China., Li X; Liaoning Cancer Hospital & Institute, Shenyang, China., Wang X; The First Affiliated Hospital, School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, China., Han L; Xuzhou Central Hospital, Xuzhou, China., Wu X; Jiangnan University Affiliated Hospital, Wuxi, China., Fan Y; Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China., Yu Y; Harbin Medical University Cancer Hospital, Harbin, China., Lv D; Taizhou Hospital of Zhejiang Province, Linhai, China., Shi J; Linyi Cancer Hospital, Linyi, China., Huang J; The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China., Zhou S; Guangxi Medical University Affiliated Tumor Hospital, Nanning, China., Han B; Shanghai Chest Hospital, Shanghai, China., Sun G; Tangshan People's Hospital, Tangshan, China., Guo Q; Shangdong Cancer Hospital, Jinan, China., Ji Y; Qingdao Central Hospital, Qingdao, China., Zhu X; Zhongda Hospital Southeast University, Nanjing, China., Hu S; Hubei Cancer Hospital, Wuhan, China., Zhang W; The First Affiliated Hospital of Nanchang University, Nanchang, China., Wang Q; Henan Cancer Hospital, Zhengzhou, China., Jia Y; The Second People's Hospital of Yibin, Yibin, China., Wang Z; Peking University Cancer Hospital, Beijing, China., Song Y; Jinling Hospital, Nanjing University School of Medicine, Nanjing, China., Wu J; The First Affiliated Hospital of Xiamen University, Xiamen, China., Shi M; Jiangsu Cancer Hospital, Nanjing, China., Li X; The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Han Z; Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China., Liu Y; The First Hospital of China Medical University, Shenyang, China., Yu Z; The Affiliated Hospital of Qingdao University, Qingdao, China., Liu AW; The Second Affiliated Hospital of Nanchang University, Nanchang, China., Wang X; Qilu Hospital of Shandong University, Jinan, China., Zhou C; Shanghai Pulmonary Hospital, Shanghai, China., Zhong D; Tianjin Medical University General Hospital, Tianjin, China., Miao L; Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China., Zhang Z; Anhui Provincial Cancer Hospital, Hefei, China., Zhao H; The Second Hospital of Anhui Medical University, Hefei, China., Yang J; The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Wang D; Army Medical Center of PLA, Daping Hospital, Daping, China., Wang Y; Peking Union Medical College Hospital, Beijing, China., Li Q; Shanghai East Hospital of Tongji University, Shanghai, China., Zhang X; Nantong Tumor Hospital, Nantong, China., Ji M; The First People's Hospital of Changzhou, Changzhou, China., Yang Z; The Second Affiliated Hospital of Chongqing University, Chongqing, China., Cui J; The First Hospital of Jilin University, Jilin, China., Gao B; Ruijin Hospital Shanghai Jiaotong University, School of Medicine, Shanghai, China., Wang B; Subei People's Hospital of Jiangsu Province, Yanghzou, China., Liu H; Anhui Provincial Cancer Hospital, Hefei, China., Nie L; Shaanxi Provincial Cancer Hospital, Xian, China., He M; Shanxi Provincial People's Hospital, Taiyuan, China., Jin S; Cancer Hospital of Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, China., Gu W; Nanjing First Hospital, Nanjing, China., Shu Y; The First Affiliated Hospital of Nanjing Medical University, Nanjing, China., Zhou T; ChangZhou Cancer Hospital, Changzhou, China., Feng J; Affiliated Hospital of Nantong University, Nantong, China., Yang X; Jiaxing No. 1 Hospital, Jiaxing, China., Huang C; Fujian Cancer Hospital, Fuzhou, China., Zhu B; Xinqiao Hospital of Army Medical University, Chongqing, China., Yao Y; First Affiliated Hospital of Xi'an Jiaotong University, Xian, China., Yao S; TopAlliance Biosciences, Rockville, MD, USA.; Shanghai Junshi Biosciences, Shanghai, China., Yu J; TopAlliance Biosciences, Rockville, MD, USA.; Shanghai Junshi Biosciences, Shanghai, China., Cai SL; Burning Rock Biotech, Guangdong, China., Cai Y; Burning Rock Biotech, Guangdong, China., Xu J; State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Zhuang W; State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Luo X; Shanghai Junshi Biosciences, Shanghai, China., Duan J; State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. duanjianchun79@163.com.; Department of Respiratory Medicine, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, China. duanjianchun79@163.com., Wang J; State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. zlhuxi@163.com.; Department of Respiratory Medicine, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, China. zlhuxi@163.com.

Publikováno v: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2024 Dec 24; Vol. 9 (1), pp. 369. Date of Electronic Publication: 2024 Dec 24.

The role of the gut microbiota in infectious complications during immunochemotherapy for diffuse large B-cell lymphoma.

Autor: Sun M; Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, 1 Min-De Road, Nanchang, Jiangxi, 330006, China., Tang D; Department of Hematology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, 1 Min-De Road, Nanchang, Jiangxi, 330006, China.; Jiangxi Provincial Key Laboratory of Hematological Diseases(2024SSY06052),Department of Hematology , The Second Affiliated Hospital of Nanchang University, 1 Min-De Road, Nanchang, Jiangxi, 330006, China., Jia J; Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, 1 Min-De Road, Nanchang, Jiangxi, 330006, China., Wu Y; Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, 1 Min-De Road, Nanchang, Jiangxi, 330006, China., Yu C; Department of Hematology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, 1 Min-De Road, Nanchang, Jiangxi, 330006, China.; Jiangxi Provincial Key Laboratory of Hematological Diseases(2024SSY06052),Department of Hematology , The Second Affiliated Hospital of Nanchang University, 1 Min-De Road, Nanchang, Jiangxi, 330006, China., Qiu R; Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, 1 Min-De Road, Nanchang, Jiangxi, 330006, China., Wang H; Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, 1 Min-De Road, Nanchang, Jiangxi, 330006, China. ndefy19002@ncu.edu.cn., Tao S; Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, 1 Min-De Road, Nanchang, Jiangxi, 330006, China. ndefy11188@ncu.edu.cn.

Publikováno v: BMC cancer [BMC Cancer] 2024 Dec 23; Vol. 24 (1), pp. 1570. Date of Electronic Publication: 2024 Dec 23.

Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL.

Autor: Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Haddad FG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Kanagal-Shamanna R; Department of Hematopathology and Molecular Diagnostics, The University of Texas MD Anderson Cancer Center, Houston, TX., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Chien K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Garris R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Nasnas C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Nasr L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Dec 20; Vol. 42 (36), pp. 4246-4251. Date of Electronic Publication: 2024 Jul 19.

Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer.

Autor: Qiu MZ; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, PR China. qiumzh@sysucc.org.cn.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, PR China. qiumzh@sysucc.org.cn., Bai Y; Department of Gastroenterology 1, Harbin Medical University Cancer Hospital, Harbin, PR China., Wang J; Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, PR China., Gu K; Oncology Ward 1, The First Affiliated Hospital of Anhui Medical University, Hefei, PR China., Yang M; Gastroenterology Ward (2), Shanxi Provincial Cancer Hospital, Taiyuan, PR China., He Y; Medical Oncology Ward 1, Anhui Provincial Cancer Hospital, Hefei, PR China., Yi C; Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, PR China., Jin Y; Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, Chengdu, PR China., Liu B; Gastroenterology Ward 3, Cancer Hospital Affiliated to Shandong First Medical University, Jinan, PR China., Wang F; Oncology Department 1, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, PR China., Chen YK; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, PR China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, PR China., Dai W; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, PR China., Jiang Y; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, PR China., Huang C; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, PR China., Xu RH; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, PR China. xurh@sysucc.org.cn.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, PR China. xurh@sysucc.org.cn., Luo HY; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, PR China. luohy@sysucc.org.cn.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, PR China. luohy@sysucc.org.cn.

Publikováno v: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2024 Dec 16; Vol. 9 (1), pp. 349. Date of Electronic Publication: 2024 Dec 16.

First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.

Autor: Lakhani NJ; START Midwest, Grand Rapids, Michigan., Papadopoulos KP; START San Antonio, San Antonio, Texas., Johnson ML; Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, Tennessee., Park H; Washington University School of Medicine, St. Louis, Missouri., Wang D; Henry Ford Hospital, Detroit, Michigan., Yap TA; University of Texas MD Anderson Cancer Center, Houston, Texas., Dowlati A; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio., Maki RG; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.; Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania., Ulahannan S; Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, Tennessee.; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma., Lynce F; Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC., Kelly K; UC Davis Comprehensive Cancer Center, UC Davis Health, Sacramento, California., Williamson S; University of Kansas Medical Center, Fairway, Kansas., Malhotra J; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey., Chen S; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Gonzalez Ortiz A; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Jankovic V; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Paccaly A; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Masinde S; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Mani J; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Lowy I; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Gullo G; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Sims T; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Kroog G; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Dec 16; Vol. 30 (24), pp. 5601-5611.